晚期乳腺癌脑转移药物研究进展

doi:10.19803/j.1672-8629.20250055

摘要/Abstract

摘要： 目的分析晚期乳腺癌脑转移（BCBM）药物现状,探索突破血脑屏障（BBB）和血-肿瘤屏障（BTB）的创新治疗策略,为提升晚期乳腺癌脑转移患者临床疗效和改善患者预后提供参考。方法根据乳腺癌亚型,分类并汇总新型抗肿瘤药物在BCBM的临床疗效。结果随着新型抗肿瘤药物的不断研发和上市,如小分子激酶抑制剂、抗体偶联药物及新型纳米制剂等药物在BCBM治疗中显现临床潜力。结论未来需深入探索BCBM发病机制,开发更加有效的治疗药物,以提升患者疗效与生存质量。

关键词: 晚期乳腺癌, 脑转移, 血脑屏障, 血-肿瘤屏障, 药物治疗, 研究进展

Abstract: Objective To analyze the current drug therapies for brain metastases from breast cancer (BCBM) and to explore innovative therapeutic strategies for overcoming the blood-brain barrier (BBB) and blood-tumor barrier (BTB) so as to enhance the clinical efficacy of treatments for patients with advanced BCBM. Methods Based on subtypes of breast cancer, novel antitumor drugs were classified and their respective clinical efficacy in BCBM was summarized. Results With the incessant development and marketing of novel anti-tumor drugs, small-molecule kinase inhibitors, such as antibody-drug conjugates and novel nanomedicines, demonstrated their potential applications in the treatment of BCBM. Conclusion The pathogenesis of BCBM requires more in-depth studies in the future, and more effective therapeutic agents need to be developed to improve life quality of patients.

Key words: Advanced Breast Cancer, Brain Metastasis, Blood-Brain Barrier, Blood-Tumor Barrier, Medication Treatment, Research Progress

中图分类号:

R979.1

叶玲, 刘晓英, 党雪菲, 李雪莲, 李纲. 晚期乳腺癌脑转移药物研究进展[J]. 中国药物警戒, 2025, 22(6): 714-720.

YE Ling, LIU Xiaoying, DANG Xuefei, LI Xuelian, LI Gang. Research Progress in Drugs for Brain Metastases from Advanced Breast Cancer[J]. Chinese Journal of Pharmacovigilance, 2025, 22(6): 714-720.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://zgywjj.magtechjournal.com/CN/10.19803/j.1672-8629.20250055

https://zgywjj.magtechjournal.com/CN/Y2025/V22/I6/714

参考文献

[1] SIEGEL RL, GIAQUINTO AN, JEMAL A. Cancer Statistics, 2024[J]. CA: a Cancer Journal for Clinicians, 2024, 74(1): 12-49.
[2] NIE Y, YING B, LU Z, et al.Predicting Survival and Prognosis of Postoperative Breast Cancer Brain Metastasis: a Population-Based Retrospective Analysis[J]. Chinese Medical Journal, 2023, 136(14): 1699-1707.
[3] SUN H, XU J, DAI S, et al.Breast Cancer Brain Metastasis: Current Evidence and Future Directions[J]. Cancer Medicine, 2023, 12(2): 1007-1024.
[4] NIIKURA N, HAYASHI N, MASUDA N, et al.Treatment Outcomes and Prognostic Factors for Patients with Brain Metastases from Breast Cancer of Each Subtype: a Multicenter Retrospective Analysis[J]. Breast Cancer Research and Treatment, 2014, 147(1): 103-112.
[5] SOFFIETTI R, AHLUWALIA M, LIN N, et al.Management of Brain Metastases According to Molecular Subtypes[J]. Nature Reviews. Neurology, 2020, 16(10): 557-574.
[6] CUSTÓDIO-SANTOS T, VIDEIRA M, BRITO MA. Brain Metasta-sization of Breast Cancer[J]. Biochimica et Biophysica Acta. Reviews on Cancer, 2017, 1868(1): 132-147.
[7] BAILLEUX C, EBERST L, BACHELOT T.Treatment Strategies for Breast Cancer Brain Metastases[J]. British Journal of Cancer, 2021, 124(1): 142-155.
[8] STEEG PS.The Blood-Tumour Barrier in Cancer Biology and Therapy[J]. Nature Reviews. Clinical Oncology, 2021, 18(11): 696-714.
[9] BRITO MA.Brain Metastases and Microenvironment[J]. Advances in Experimental Medicine and Biology, 2021, 1329: 325-349.
[10] ERICKSON MA, BANKS WA.Transcellular Routes of Blood-Brain Barrier Disruption[J]. Experimental Biology and Medicine (Maywood, N.J.), 2022, 247(9): 788-796.
[11] TASHIMA T.Brain Cancer Chemotherapy through a Delivery System across the Blood-Brain Barrier into the Brain Based on Receptor-Mediated Transcytosis Using Monoclonal Antibody Conjugates[J]. Biomedicines, 2022, 10(7): 1597.
[12] YANG Z, MENG J, MEI X, et al.Brain Radiotherapy with Pyrotinib and Capecitabine in Patients with ERBB2-Positive Advanced Breast Cancer and Brain Metastases: a Nonrandomized Phase 2 Trial[J]. JAMA Oncology, 2024, 10(3): 335-341.
[13] CURIGLIANO G, MUELLER V, BORGES V, et al.Tucatinib Versus Placebo Added to Trastuzumab and Capecitabine for Patients with Pretreated HER2+ Metastatic Breast Cancer with and without Brain Metastases (HER2CLIMB): Final Overall Survival Analysis[J]. Annals of Oncology, 2022, 33(3): 321-329.
[14] LIN NU, MURTHY RK, ABRAMSON V, et al.Tucatinib vs Placebo, Both in Combination with Trastuzumab and Capecitabine, for Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer in Patients with Brain Metastases: Updated Exploratory Analysis of the HER2CLIMB Randomized Clinical Trial[J]. JAMA Oncology, 2023, 9(2): 284.
[15] LIN NU, PEGRAM M, SAHEBJAM S, et al.Pertuzumab Plus High-Dose Trastuzumab in Patients with Progressive Brain Metastases and HER2-Positive Metastatic Breast Cancer: Primary Analysis of a Phase II Study[J].Journal of Clinical Oncology, 2021, 39(24): 2667-2675.
[16] JERUSALEM G, PARK YH, YAMASHITA T, et al.Trastuzumab Deruxtecan in HER2-Positive Metastatic Breast Cancer Patients with Brain Metastases: a DESTINY-Breast01 Subgroup Analysis[J]. Cancer Discovery, 2022, 12(12): 2754-2762.
[17] BARTSCH R, BERGHOFF AS, FURTNER J, et al.Trastuzumab Deruxtecan in HER2-Positive Breast Cancer with Brain Metastases: a Single-Arm, Phase 2 Trial[J]. Nature Medicine, 2022, 28(9): 1840-1847.
[18] HARBECK N, CIRUELOS E, JERUSALEM G, et al.Trastuzumab Deruxtecan in HER2-Positive Advanced Breast Cancer with or without Brain Metastases: a Phase 3b/4 Trial[J]. Nature Medicine, 2024, 30(12): 3717-3727.
[19] TOLANEY SM, SAHEBJAM S, LE RHUN E, et al.A Phase II Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor-Positive Breast Cancer[J]. Clinical Cancer Research, 2020, 26(20): 5310-5319.
[20] SHAH N, MOHAMMAD AS, SARALKAR P, et al.Investigational Chemotherapy and Novel Pharmacokinetic Mechanisms for the Treatment of Breast Cancer Brain Metastases[J]. Pharmacological Research, 2018, 132: 47-68.
[21] OSSWALD M, BLAES J, LIAO Y, et al.Impact of Blood-Brain Barrier Integrity on Tumor Growth and Therapy Response in Brain Metastases[J]. Clinical Cancer Research, 2016, 22(24): 6078-6087.
[22] ADKINS CE, MITTAPALLI RK, MANDA VK, et al.P-Glycoprotein Mediated Efflux Limits Substrate and Drug Uptake in a Preclinical Brain Metastases of Breast Cancer Model[J]. Frontiers in Pharmacology, 2013, 4: 136.
[23] WANG T, CHEN J, YANG J, et al.CSCO Expert Consensus on the Diagnosis and Treatment of Breast Cancer Brain Metastasis[J]. Translational Breast Cancer Research, 2022, 3: 22.
[24] BAZAN F, DOBI E, ROYER B, et al.Systemic High-Dose Intravenous Methotrexate in Patients with Central Nervous System Metastatic Breast Cancer[J]. BMC Cancer, 2019, 19(1): 1029.
[25] LI F, HUANG T, TANG Y, et al.Utidelone Inhibits Growth of Colorectal Cancer Cells Through ROS/JNK Signaling Pathway[J]. Cell Death & Disease, 2021, 12(4): 338.
[26] YAN Y, LV HM, LIU XL, et al.Utidelone Plus Bevacizumab for the Treatment of HER2-Negative Breast Cancer Brain Metastases (U-BOMB): a Multicenter, Single-Arm Phase II Study[J]. Journal of Clinical Oncology, 2024, 24(16suppl): 1081.
[27] BAI X, ZHANG Y, DING W et al. Efficacy of Bevacizumab in the Treatment of Refractory Brain Edema of Metastatic Tumors from Different Sources[J]. Neurological Research, 2021, 43(12): 955-960.
[28] LEONE JP, EMBLEM KE, WEITZ M, et al.Phase II Trial of Carboplatin and Bevacizumab in Patients with Breast Cancer Brain Metastases[J]. Breast Cancer Research, 2020, 22(1): 131.
[29] CHEN TW, DAI MS, TSENG LM, et al.Whole-Brain Radiotherapy Alone vs Preceded by Bevacizumab, Etoposide, and Cisplatin for Untreated Brain Metastases from Breast Cancer: a Randomized Clinical Trial[J]. JAMA Oncology, 2024, 10(3): 325-334.
[30] JIANG Z, OUYANG Q, SUN T, et al.Toripalimab Plus Nab-Paclitaxel in Metastatic or Recurrent Triple-Negative Breast Cancer: a Randomized Phase 3 Trial[J]. Nature Medicine, 2024, 30(1): 249-256.
[31] CORTES J, RUGO HS, CESCON DW, et al.Pembrolizumab Plus Chemotherapy in Advanced Triple-Negative Breast Cancer[J]. The New England Journal of Medicine, 2022, 387(3): 217-226.
[32] AHMED KA, KIM Y, ARRINGTON JA, et al.Nivolumab and Stereotactic Radiosurgery for Patients with Breast Cancer Brain Metastases: a Nonrandomized, Open-Label Phase 1b Study[J]. Advances in Radiation Oncology, 2021, 6(6): 100798.
[33] KARIM AM, EUN KWON J, ALI T, et al.Triple-Negative Breast Cancer: Epidemiology, Molecular Mechanisms, and Modern Vaccine-Based Treatment Strategies[J]. Biochemical Pharmacology, 2023, 212: 115545.
[34] SONG Y, BARRY WT, SEAH DS, et al.Patterns of Recurrence and Metastasis in BRCA1/BRCA2-Associated Breast Cancers[J]. Cancer, 2020, 126(2): 271-280.
[35] ROBSON ME, TUNG N, CONTE P, et al.Olympiad Final Overall Survival and Tolerability Results: Olaparib Versus Chemotherapy Treatment of Physician's Choice in Patients with a Germline BRCA Mutation and HER2-Negative Metastatic Breast Cancer[J]. Annals of Oncology, 2019, 30(4): 558-566.
[36] DIÉRAS V, HAN HS, KAUFMAN B, et al. Veliparib with Carboplatin and Paclitaxel in BRCA-Mutated Advanced Breast Cancer (BROCADE3): a Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial[J]. The Lancet. Oncology, 2020, 21(10): 1269-1282.
[37] BARDIA A, RUGO HS, TOLANEY SM, et al.Final Results from the Randomized Phase III ASCENT Clinical Trial in Metastatic Triple-Negative Breast Cancer and Association of Outcomes by Human Epidermal Growth Factor Receptor 2 and Trophoblast Cell Surface Antigen 2 Expression[J]. Journal of Clinical Oncology, 2024, 42(15): 1738-1744.
[38] ALAKLABI S, ELIJAH E, ROY AM, et al.Real World Outcomes of Sacituzumab Govitecan in Metastatic Breast Cancer Patients: a Single Institution Experience[C]. Poster Presented at 40th Annual Miami Breast Cancer Conference, 2023.
[39] YU T, LU Y, FANG J, et al.Chimeric Antigen Receptor-Based Immunotherapy in Breast Cancer: Recent Progress in China[J]. Cancer, 2024, 130(S8): 1378-1391.